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RTQA procedures has been strongly advocated by the Global 
Harmonisation Group[7].  
Ensuring RT compliance with protocol guidelines involves 
however gradually more resources-intensive procedures 
which are also labor intensive and are not cost-neutral. This 
will consequentially have a significant impact on the overall 
study budget. This financial investment is of paramount 
importance, as non-adherence to protocol-specified RT 
requirements in prospective trials is very frequent[8, 9]. The 
European Organisation for the Research and Treatment of 
Cancer (EORTC) Radiation Oncology Group started to 
implement RTQA strategies in the 1980s[10], including on how 
to write a protocol for RT trials[11, 12], defining RTQA 
procedures (such as benchmark case, dummy run and 
complex treatment dosimetry checks)[7], assuring prospective 
individual case review feasibility and implementing an 
electronic data-exchange platform[3].  
 
Keywords: Quality assurance, RTQA, prospective trial, 
patient’s outcome, toxicity 
 
References: 
[1] Budiharto T, Musat E, Poortmans P, Hurkmans C, Monti A, 
Bar-Deroma R, et al. Profile of European radiotherapy 
departments contributing to the EORTC Radiation Oncology 
Group (ROG) in the 21st century. Radiother Oncol. 
2008;88:403-10. 
[2] Gondi V, Cui Y, Mehta MP, Manfredi D, Xiao Y, Galvin JM, 
et al. Real-time pretreatment review limits unacceptable 
deviations on a cooperative group radiation therapy 
technique trial: quality assurance results of RTOG 0933. 
International journal of radiation oncology, biology, physics. 
2015;91:564-70. 
[3] Fairchild A, Aird E, Fenton PA, Gregoire V, Gulyban A, 
Lacombe D, et al. EORTC Radiation Oncology Group quality 
assurance platform: establishment of a digital central review 
facility. Radiother Oncol. 2012;103:279-86. 
[4] Ohri N, Shen X, Dicker AP, Doyle LA, Harrison AS, 
Showalter TN. Radiotherapy Protocol Deviations and Clinical 
Outcomes: A Meta-analysis of Cooperative Group Clinical 
Trials. J Natl Cancer Inst. 2013;105:387-93. 
[5] Weber DC, Tomsej M, Melidis C, Hurkmans CW. QA makes 
a clinical trial stronger: Evidence-based medicine in radiation 
therapy. Radiother Oncol. 2012;105:4-8 
[6] Peters LJ, O'Sullivan B, Giralt J, Fitzgerald TJ, Trotti A, 
Bernier J, et al. Critical impact of radiotherapy protocol 
compliance and quality in the treatment of advanced head 
and neck cancer: results from TROG 02.02. J Clin Oncol. 
2010;28:2996-3001. 
[7] Melidis C, Bosch WR, Izewska J, Fidarova E, Zubizarreta E, 
Ulin K, et al. Global harmonization of quality assurance 
naming conventions in radiation therapy clinical trials. 
International journal of radiation oncology, biology, physics. 
2014;90:1242-9. 
[8] Musat E, Roelofs E, Bar-Deroma R, Fenton P, Gulyban A, 
Collette L, et al. Dummy run and conformity indices in the 
ongoing EORTC low-grade glioma trial 22033-26033: First 
evaluation of quality of radiotherapy planning. Radiother 
Oncol. 2010;95:218-24. 
[9] Coskun M, Straube W, Hurkmans CW, Melidis C, de Haan 
PF, Villa S, et al. Quality assurance of radiotherapy in the 
ongoing EORTC 22042-26042 trial for atypical and malignant 
meningioma: results from the dummy runs and prospective 
individual case Reviews. Radiat Oncol. 2013;8:23. 
[10] Weber DC, Poortmans PM, Hurkmans CW, Aird E, 
Gulyban A, Fairchild A. Quality assurance for prospective 
EORTC radiation oncology trials: the challenges of advanced 
technology in a multicenter international setting. Radiother 
Oncol. 2011;100:150-6. 
[11] Fairchild A, Bar-Deroma R, Collette L, Haustermans K, 
Hurkmans C, Lacombe D, et al. Development of clinical trial 
protocols involving advanced radiation therapy techniques: 
the European Organisation for Research and Treatment of 
Cancer Radiation Oncology Group approach. Eur J Cancer. 
2012;48:1048-54. 
[12] Bolla M, Bartelink H, Garavaglia G, Gonzalez D, Horiot 
JC, Johansson KA, et al. EORTC guidelines for writing 
protocols for clinical trials of radiotherapy. Radiother Oncol. 
1995;36:1-8. 
 
232 
Yield study and optimization of nuclear isotopes for cancer 
treatment and diagnostics with ISOLTRAP/CERN 
A. Welker1,8, N.A.S Althubiti2, D. Atanasov3, K. Blaum3, F. 
Herfurth4, S. Kreim3, U. Koester5, D. Lunney6, M. Mougeot6, 
V. Manea3, D. Neidherr4, M. Rosenbusch7, L. Schweikhard7, F. 
Wienholtz7, R. Wolf3, K. Zuber1 
1 Institut für Kern- und Teilchenphysik, Technische Universität 
Dresden, Zellescher Weg 19, 01069 Dresden, Germany; 
2 University of Manchester, Manchester, United Kingdom;  
3 Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 
69117 Heidelberg, Germany;  
4 GSI Helmholtzzentrum für Schwerionenforschung GmbH, 
Planckstr. 1, 64291 Darmstadt, Germany; 
5 Institute-Laue-Langevin, 71 avenue des Martyrs – CS 20156 – 
38042 Grenoble Cedex 9; 
6 CSNSM-IN2P3-CNRS, 91405 Orsay Campus, bât. 104, 108, 
France;  
7 Ernst-Moritz-Arndt-Universität, Institut für Physik, Felix-
Hausdorff-Str. 6, 17487 Greifswald, Germany;  
8 CERN, Geneva 23, 1211 Geneva Switzerland 
 
Purpose: The ISOLDE [1] facility at CERN provides a wide 
choice (>1000 different radioisotopes) of mass-separated ion 
beams. These serve a variety of disciplines, including 
radiochemistry, radiobiology and preclinical studies for 
nuclear medicine. Recently the quadruplet of terbium (Tb) 
isotopes covering all modalities of nuclear medicine gained 
considerable interest [2]. 
Materials/Methods: Neutron-deficient lanthanide isotopes 
such as 149,152,155Tb are produced at ISOLDE by 1.4 GeV 
proton induced spallation of tantalum foil targets. The 
radionuclides diffuse out of the 2000 °C hot target and are 
surface or laser ionized, accelerated to 30-60 keV and mass 
separated. Due to the chemical similarity of the lanthanides 
the separated beam is not mono-isotopic but also contains 
isobars of the selected mass plus sidebands of oxide ions 16 
mass units less. Most of these are radioactive with different 
half-lives and a wealth of gamma rays which renders difficult 
a quick on-line assessment of the beam composition by 
gamma ray spectrometry.  
We present a new tool for this purpose, the so called multi-
reflection time-of-flight mass spectrometer (MR-TOF MS) [3] 
which is used at the high-resolution mass spectrometer 
ISOLTRAP [4]. With the support of the spectrometer it is 
possible to analyse the composition of the collected beam 
immediately and vary the production parameters in order to 
enhance even more the purity of the isotope of interest. 
Results: Using ISOLTRAP’s MR-TOF MS the yield and purity of 
the dysprosium beams were successfully optimized on-line. 
To enhance the usable terbium activity, the dysprosium (Dy) 
isobars of the isotopes of interest were laser-ionised and 
collected on a Zn foil, the creation of terbium taking place 
directly in the sample by beta decay. The foils where shipped 
after the implantation to PSI where the preparation of the 
radionuclide pure product took place. 
Conclusion: We will present in this contribution the results 
from terbium collection campaigns taking place in the last 
three years at ISOLDE. The beam analysis capabilities of 
ISOLTRAP will be presented, as well as recent results 
concerning the composition and purity of ISOLDE dysprosium 
beams. 
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